Antibody Therapy Market - By Type [Monoclonal Antibodies (mAbs) {Oncology, Autoimmune Disease, Infectious Disease}, Antibody-drug Conjugates (ADCs)], By End-use (Hospitals, Specialty Centers) - Global Forecast, 2023

Description

List of Tables

Antibody therapy market size is projected to expand at 11.8% CAGR from 2023 to 2032. The increasing prevalence of chronic diseases, such as cancer and autoimmune disorders, is fueling the demand for several targeted and personalized treatments.

The increasing advancements in biotechnology and immunology are encouraging the development of novel and more effective antibody therapies. For instance, in September 2023, Manaolana Oncology Inc. was officially launched through a collaboration between The University of Texas MD Anderson Cancer Center and Panacea Venture to develop and advance in antibody-based therapies for targeting the emerging cancer antigens. Additionally, the growing awareness of the benefits of antibody therapy, including reduced side effects and improved treatment outcomes will escalate their demand. The rising investments in R&D activities for antibody-based drugs and the expanding application scope in various medical fields will further drive the market expansion.

The antibody therapy industry is segregated into type, end-use, and region.

The market share from the antibody-drug conjugates segment is estimated to rise at 11.6% CAGR from 2023 to 2032. This is mainly on account of the increasing research and development activities, the rising prevalence of cancer, and the surging advancements in biotechnology. High demand for targeted and personalized therapies will also drive the segment growth.

Antibody therapy market share from the specialty centers end-use segment is projected to rise at 12.5% CAGR between 2023 and 2032. The growth can be attributed to the growing prevalence of chronic diseases, expanding patient pool seeking specialized care, and the rising advancements in precision medicine. Moreover, specialty centers play a crucial role in delivering targeted treatments, driving the adoption of antibody therapies in these centers.

Regionally, the Europe antibody therapy market size is projected to expand at 11.6% growth rate from 2023 and 2032, due to the increasing prevalence of chronic diseases and the rising biopharmaceutical R&D investments. Furthermore, the growing awareness about personalized medicine, and the presence of favorable regulatory environment will fuel the demand for antibody therapies across the region.

Product Code: 5195

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & workings
- 1.2.1 Data collection
1.3 Forecast calculations
1.4 COVID-19 impact analysis at global level
1.5 Data sources
- 1.5.1 Primary
- 1.5.2 Secondary
  - 1.5.2.1 Paid sources
  - 1.5.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Antibody therapy market 360 degree synopsis, 2018 - 2032 (USD Million)
- 2.1.1 Business trends
- 2.1.2 Regional trends
- 2.1.3 Type trends
- 2.1.4 End-use trends

Chapter 3 Antibody Therapy Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of chronic and infectious disease worldwide
  - 3.2.1.2 Growing R&D activities
  - 3.2.1.3 High rate of adoption and approval in the U.S. and Europe
  - 3.2.1.4 Booming biologics industry
  - 3.2.1.5 Rising applications of antibody therapy
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of some monoclonal antibody therapeutics
  - 3.2.2.2 Complex manufacturing processes and logistical challenges
3.3 Growth potential analysis
- 3.3.1 By type
- 3.3.2 By end-use
3.4 COVID- 19 impact analysis
3.5 Pipeline products
- 3.5.1 Monoclonal antibodies
- 3.5.2 Antibody drug conjugates
3.6 Regulatory landscape
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company market share analysis, 2022
4.3 Competitive analysis of major market players, 2022
4.4 Company positioning matrix, 2022
4.5 Strategy outlook matrix, 2022

Chapter 5 Antibody Therapy Market Size and Forecast, By Type, 2018-2032 (USD Million)

5.1 Key trends, by type
5.2 Monoclonal antibodies (mAbs)
- 5.2.1 Oncology
- 5.2.2 Autoimmune diseases
- 5.2.3 Infectious diseases
- 5.2.4 Other monoclonal antibodies (mAbs)
5.3 Antibody-drug conjugates (ADCs)

Chapter 6 Antibody Therapy Market Size and Forecast, By End-use, 2018-2032 (USD Million)

6.1 Key trends, by end-use
6.2 Hospitals
6.3 Specialty centers
6.4 Other end-users

Chapter 7 Antibody Therapy Market Size and Forecast, By Region, 2018-2032 (USD Million)

7.1 Key trends, by region
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
7.3 Europe
- 7.3.1 Germany
- 7.3.2 UK
- 7.3.3 France
- 7.3.4 Italy
- 7.3.5 Spain
- 7.3.6 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Australia
- 7.4.5 Singapore
- 7.4.6 Rest of Asia Pacific
7.5 Latin America
- 7.5.1 Brazil
- 7.5.2 Mexico
- 7.5.3 Argentina
- 7.5.4 Rest of Latin America
7.6 Middle East & Africa
- 7.6.1 South Africa
- 7.6.2 Saudi Arabia
- 7.6.3 UAE
- 7.6.4 Kuwait
- 7.6.5 Egypt
- 7.6.6 Rest of Middle East & Africa

Chapter 8 Company Profiles

8.1 F. Hoffmann-La Roche Ltd.
8.2 AbbVie, Inc.
8.3 Amgen Inc.
8.4 Bristol-Myers Squibb Company
8.5 Johnson & Johnson Services, Inc.
8.6 Seagen
8.7 Merck & Co., Inc.
8.8 Regeneron Pharmaceuticals Inc.
8.9 Novartis AG
8.10 AstraZeneca
8.11 Eli Lilly and Company
8.12 GlaxoSmithKline plc.
8.13 Takeda Pharmaceutical Company Ltd.